Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Zynerba Pharmaceuticals, Inc. (ZYNE)
|
|
| Cash Flow Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Net income | -10.8 | -10.1 | -8.0 | -8.7 | -9.9 | -8.5 | -8.8 | -10.6 |
| Depreciation and amortization [+] | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Depreciation | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Stock-based compensation | 0.8 | 0.8 | 1.0 | 1.0 | 1.1 | 1.2 | 1.0 | 1.6 |
| Change in working capital [+] | 1.9 | 1.6 | 0.4 | -2.0 | 1.0 | -0.2 | 0.1 | -1.2 |
| Other current assets | 0.0 | 1.0 | 0.6 | -1.8 | 0.4 | 0.8 | 1.0 | -2.1 |
| Accounts payable | 0.3 | 0.3 | 0.3 | -0.1 | 0.1 | -0.3 | -0.8 | 0.9 |
| Accrued expenses | 1.6 | 0.4 | -0.6 | -0.1 | 0.5 | -0.8 | -0.2 | 0.1 |
| Other operating activities | -0.4 | -0.3 | 0.9 | -0.1 | -0.2 | 7.7 | -0.2 | 0.1 |
| Cash from operations | -8.4 | -7.9 | -5.7 | -9.7 | -7.9 | 0.2 | -7.8 | -10.0 |
| |
| Capital expenditures | 0.0 | -0.1 | 0.0 | -0.1 | 0.0 | -0.1 | 0.0 | 0.0 |
| Purchases of property and equipment | 0.0 | -0.1 | 0.0 | -0.1 | | -0.1 | | |
| Cash from investing | 0.0 | -0.1 | 0.0 | -0.1 | 0.0 | -0.1 | 0.0 | 0.0 |
| |
| Issuance of common stock, net | 0.1 | 1.8 | 0.5 | 3.4 | 0.9 | 1.8 | | |
| Other cash from financing | -0.1 | 0.0 | -0.1 | -0.2 | -0.2 | 0.0 | | -0.1 |
| Cash from financing | 0.0 | 1.7 | 0.4 | 3.2 | 0.7 | 1.7 | 0.0 | -0.1 |
| |
| Free cash flow | -8.4 | -8.0 | -5.7 | -9.8 | -7.9 | 0.1 | -7.8 | -10.0 |
| Per share (diluted) | ($0.17) | ($0.16) | ($0.13) | ($0.22) | ($0.19) | $0.00 | ($0.20) | ($0.25) |
| |
|